

## Influenza A(H3N2) egg-derived<sup>1</sup> candidate vaccine viruses for development and production of vaccines for use in the 2026 southern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)<sup>2</sup>

26 September 2025 (*Last updated 02 February 2026*)

**Candidate vaccine viruses antigenically like A/Singapore/GP20238/2024 (egg-derived) - Accession number (GISAID): EPI\_ISL\_19871656**

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Singapore/GP20238/2024		Wild type	VIDRL, Australia	VIDRL, Australia
	IVR-277	classical	Seqirus	
A/Valladolid/1187/2025		Wild type	FCI, UK	MHRA, UK
A/Minnesota/15/2025		Wild type	CDC, USA	CDC, USA
A/Nepal/N042/2025		Wild type	VIDRL, Australia	VIDRL, Australia

**Institutes contact details for candidate vaccine virus orders/information:**

**VIDRL:** [enquiries@influenzacentre.org](mailto:enquiries@influenzacentre.org)

**MHRA:** [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

**WHO CCs and ERLs:** [http://www.who.int/influenza/gisrs\\_laboratory/collaborating\\_centres](http://www.who.int/influenza/gisrs_laboratory/collaborating_centres)

<sup>1</sup> For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

<sup>2</sup> <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

## Reference antigens (freeze-dried)

Parent virus	Starting materials		Ref Ag Lot number	Unitage	Available from
	Candidate vaccine virus	Egg or cell		( $\mu$ g HA/ml)	
A/Singapore/GP20238/2024	IVR-227	Egg	2025/153B	78	TGA, Australia
			H3-Ag-2510	69	CBER/FDA, USA
			25/220	48	MHRA, UK

## Sheep Antisera

Purified HA from		Order Lot number	Available from	
Parent virus	Egg or cell			
A/Valladolid/1187/2025-like	Egg	H3-Ab-2514	CBER/FDA, USA	
A/Singapore/GP20238/2024-like		25/226	MHRA, UK	
		AS466	TGA, Australia	

## WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:

MHRA: [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

TGA: [influenza.reagents@tga.gov.au](mailto:influenza.reagents@tga.gov.au)

For reagents available from CBER, email [CBERShippingRequests@fda.hhs.gov](mailto:CBERShippingRequests@fda.hhs.gov).

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>).

For general enquiries, please contact [gisrs-whohq@who.int](mailto:gisrs-whohq@who.int)